MoonLake Immunotherapeutics (NASDAQ:MLTX) — Market Cap & Net Worth
Market Cap & Net Worth: MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics (NASDAQ:MLTX) has a market capitalization of $1.24 Billion ($1.24 Billion) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8135 globally and #2323 in its home market, demonstrating a 7.81% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MoonLake Immunotherapeutics's stock price $19.19 by its total outstanding shares 72852170 (72.85 Million). Review MoonLake Immunotherapeutics (MLTX) total liabilities to assess the company's total debt and financial obligations.
MoonLake Immunotherapeutics Market Cap History: 2020 to 2026
MoonLake Immunotherapeutics's market capitalization history from 2020 to 2026. Data shows growth from $828.33 Million to $1.40 Billion (11.26% CAGR).
Index Memberships
MoonLake Immunotherapeutics is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.05% | #225 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #865 of 3165 |
Weight: MoonLake Immunotherapeutics's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
MoonLake Immunotherapeutics Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MoonLake Immunotherapeutics's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MLTX by Market Capitalization
Companies near MoonLake Immunotherapeutics in the global market cap rankings as of June 18, 2026.
Key companies related to MoonLake Immunotherapeutics by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
MoonLake Immunotherapeutics Historical Marketcap From 2020 to 2026
Between 2020 and today, MoonLake Immunotherapeutics's market cap moved from $828.33 Million to $ 1.40 Billion, with a yearly change of 11.26%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.40 Billion | +45.60% |
| 2025 | $960.19 Million | -75.66% |
| 2024 | $3.94 Billion | -10.33% |
| 2023 | $4.40 Billion | +475.14% |
| 2022 | $764.95 Million | +6.17% |
| 2021 | $720.51 Million | -13.02% |
| 2020 | $828.33 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of MoonLake Immunotherapeutics was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.24 Billion USD |
| MoneyControl | $1.24 Billion USD |
| MarketWatch | $1.24 Billion USD |
| marketcap.company | $1.24 Billion USD |
| Reuters | $1.24 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplan… Read more